The development of low molecular weight inhibitors of hepatitis C virus (HCV) replication has been hindered by the lack of a good cell-based system that models the entire HCV replication cycle. To date the only two therapies approved for the treatment of HCV infection are interferon (IFN)-α and the nucleoside analogue, ribavirin. We have created a cell-based system that allows for the accurate quantification of the replication of an HCV-like RNA template by proteins that are encoded for by the HCV genome. The system consists of a cell line that constitutively produces luciferase in response to the production of functional HCV replicative proteins. The 293B4α cell line has been formatted into a semi-high throughput, cell-based screen for inhibitors of HCV replication. When these cells were treated with either IFN-α or -β, luciferase production decreased in a dose-respon-sive manner. Counterscreening these molecules in another cell line, 293SVLuc, in which luciferase production in not dependent the presence of functional HCV proteins, showed that the inhibition of luciferase in the 293B4α cell line was due to inhibition of the replication of the HCV-like RNA template and not anti-cellular or -luciferase activity. Moreover, when the 293B4α cell line was treated with the ribonucleoside analogue, 3′-deoxycytidine, luciferase decreased in a dose-responsive manner. 3′-deoxyguanosine and 3′-deoxyuridine did not inhibit luciferase production and 3′deoxyadenosine was too cytotoxic to determine if it had any anti-HCV activity.
Hepatitis C virus (HCV), a member of the Flaviviridae family, is an enveloped, positive-stranded RNA virus that causes both acute and chronic infection of the liver (Major et al., 2001) . Failure to clear the virus frequently results in the progression to chronic liver disease, cirrhosis and hepatocellular carcinoma. Because of this, HCV infection has become the leading cause for liver transplantation in the developed nations.
The HCV genomic RNA is approximately 9.6 kb in length and consists of a 5′ untranslated region (UTR), a single long open reading frame (ORF) that encodes the viral polyprotein, and a 3′ UTR. The sequence of the 5′ UTR is highly conserved and contains an internal ribosome entry site (IRES) that allows for cap-independent translation of the viral ORF (Major et al., 2001) . The polyprotein that is encoded by the ORF is approximately 3000 amino acids in length and produces at least ten viral proteins from co-and post-translational processing by cellular and viral proteinases. The structural proteins are located in the amino-terminal third of the polyprotein and the non-structural proteins are found in the carboxy-terminal two-thirds.
Currently, the only approved treatments for individuals infected with HCV are interferon (IFN)-α (either in the native or pegylated forms) alone or in combination with the nucleoside analogue ribavirin. Recent clinical studies that compared the efficacy of IFN with and without ribavirin showed that IFN plus ribavirin was approximately 25% more efficacious than IFN alone. However, only approximately 40% of the IFN plus ribavirin group developed a sustained response to treatment (McHutchison et al., 1998; Lavachy et al., 1999) . This response rate can be improved to >60% through the use of a pegylated form of IFN-α, which was shown to be more effective and convenient than conventional IFN therapy (Shiffman et al., 1999) .
Several laboratories have reported that IFN could inhibit HCV replication in cell-based models of HCV replication (Lohmann et al., 1999; Blight et al., 2000; Chung et al., 2001; Gou et al., 2001) . Much work has been done on determining the mechanism of action of IFN in inhibiting HCV replication (for a review see Hu et al., 2001) . Recently, it has been shown that the inhibition of HCV replication by IFN occurs by an MxA-independent pathway that may involve the IFN-induced PKR protein Introduction kinase (Gale et al., 1997 (Gale et al., , 1998 Frese et al., 2001) . Moreover, the sensitivity of the virus to the IFN-induced PKR protein kinase-mediated antiviral state may be dependent on the sequence of the viral NS5A gene (Gale et al., 1997 (Gale et al., , 1998 Murakami et al., 1999; Polyak et al., 1999) . Interestingly, it has been reported that the HCV core protein may actually act as an activator of the promoter of the IFN-inducible 2′-5′-oligoadenylate synthetase gene (Naganuma et al., 2000) .
We have previously described a stably-transfected, cellbased system (293B4α) which uses luciferase production as a measure of the replication of an HCV-like RNA template by the HCV RNA dependent RNA polymerase (RdRp) (King et al., 2002b) . This 'HCV-like' chimeric RNA consists of an antisense copy of the luciferase gene flanked by the 5′ and 3′ UTRs of the HCV negativestrand RNA that acts as a template for negative-strand to positive-strand RNA synthesis. The newly synthesized 'positive-strand' RNA can then be used as a template for cap-independent protein translation, which results in the production of luciferase. Furthermore, we have established that the level of luciferase production in these cells accurately reflects the level of replication of the HCV-like chimeric template.
Here we report that we have formatted this cell-based system into a medium-throughput screen for inhibitors of HCV replication and showed that in the 293B4α cell line replication of the HCV-like RNA template can be inhibited by IFN-α, IFN-β and 3′-deoxycytidine in a dosedependent fashion.
Materials and methods

Chemicals
Interferon-α and -β, and ribavirin were purchased from Sigma Chemical Corp (St. Louis, Mo., USA) and ICN Biomedicals Inc. (Aurora, OH, USA). The 3′-deoxynucleoside analogues also were purchased from ICN Biomedicals Inc. Lamivudine was a gift from Raymond Schinazi (Emory University, Atlanta, Ga., USA).
Cells lines and culture conditions
293B4α and 293SVLuc cell lines have been described previously (King et al., 2002b) and were maintained in Dulbecco's modified Eagles medium (DMEM) supplemented with fetal bovine sera (5%; FBS), penicillin (50 units per ml) and streptomycin (50 µg per ml) with the addition of the following selection agents: zeocin (500 µg per ml) and G418 (500 µg per ml) for the 293B4α cell line and zeocin (500 µg per ml) for the 293SVLuc cell line. All cells were incubated at 37°C and 5% CO 2 .
The 293B4α cell line was created by stably transfecting the 293 human embryonic kidney cell line with a plasmid that contained a cDNA copy of the HCV 1b genome under the transcriptional control of the chicken β-actin promoter and a second plasmid, pMJ050, that encodes a chimeric RNA template for the HCV RdRp. This template consists of the 5′ and 3′ UTR of the HCV-negative strand RNA, the antisense sequence of the firefly luciferase gene and the hepatitis δ ribozyme. The RNA that is transcribed from pMJ050 can serve as a template for the HCV replicase complex resulting in the constitutive production of luciferase.
The 293SVLuc cell line consists of 293 cells that were stably transfected with a plasmid that contains the firefly luciferase gene under the transcriptional control of the SV40 promoter. This cell line constitutively produces luciferase.
Virus
Vesicular stomatitis virus (VSV) was a gift from Bruce Korant (DuPont Pharmaceuticals Co. Wilmington, Del., USA) and mengovirus (strain is + ; Fleishman & Simon 1973) was a gift from Edward Simon (Purdue University). Stocks of both viruses were created and titred by plaque assay using HeLa cells. Individual aliquots were stored at -80°C Anti-HCV assay 293B4α and 293SVLuc cells were seeded into the wells of 96-well microtitre plates (3×10 3 cells in 50 µl of DMEM+5% FBS/well) and incubated overnight. Various concentrations of compound(s) were added and the plates were incubated at 37°C for 36 to 48 h (five days for the experiments with IFN to allow for the establishment of the IFN-induced antiviral state). Luciferase activity was quantified as described below. The cytotoxicity of the compounds was established using the same protocol with the exception of using 293SVLuc cells in place of 293B4α cells. The concentration of compound that inhibits 50% of luciferase activity (IC 50 ) and cell growth (TC 50 ) was determined by linear regression.
Luciferase assay
Luciferase levels were determined in 293B4α and 293SVLuc using the Bright-Glo Luciferase Assay System as directed by the manufacturer (Promega Corp., Madison, Wisc., USA). Luciferase units were quantified using a TopCount NXT Microplate Scintillation and Luminescence Counter (Packard, Downers Grove, Ill., USA).
Combination experiments
For the combination of IFN-α and -β, compounds were combined at concentrations near their experimentally determined IC 50 values. The mixture then was serially diluted 32-fold using twofold dilutions. This dilution set was designated the 1:1 combination. Additional dilution series were created with ratios of 3:1 and 1:3 of the com-pounds' IC 50 . Since an IC 50 value for ribavirin could not be established, in the ribavirin and IFN combination experiments, ribavirin was used at the highest concentration that did not exhibit cytotoxicity, 0.3 µM and IFN was used at its independently established IC 50 value, three times IC 50 value and ten times IC 50 value.
Combination Index (CI) values were calculated using the Chou and Talalay model (Chou & Talalay, 1984) for drug combinations as determined by the CalcuSyn Software Package (BioSoft). Each combination experiment was performed three times with each combination being tested in duplicate per experiment. CI values between experiments for identical combinations varied less than 15% and the internal duplicates varied less than 10%. CI values <0.8 denote synergy; >0.8 but <1.2 denote additivity; and >1.2 denote antagonism (King et al., 2002a) .
Western blot assay of luciferase
Cells (1×10 6 cells per well) were plated in 6-well tissue culture plates. Twenty-four hours later, cells were harvested by scraping with a rubber policeman and lysed by resuspension in 50 µl of lysis buffer (50mM Tris, pH 8.0; 1mM EDTA; and 1% NP-40). The lysate was clarified by microcentrifugation and stored at -20°C.
Fifteen micrometres of the clarified lysate was mixed with 5 µl of 4X loading buffer (500mM Tris-HCl, pH 6.8; 4% SDS; 20% glycerol; 40mM DTT; and 0.02% bromophenol blue) and boiled briefly before loading onto a 4-12% gradient poly-acrylamide gel. Proteins were separated by size by electrophoresis and then transferred to a nitrocellulose filter. Firefly luciferase was detected by Western blot analysis using commercially-available monoclonal antibodies (mAbs) that react specifically the protein (Promega Corp.) and the WesternBreeze Kit for mouse Ab (Invitrogen, Carlsbad, Calif., USA).
Interferon assay
293, HUH-7 and HeLa cells were plated in 96-well microtitre plates (1×10 4 cells/well) and treated with various concentrations of IFN-α and -β. Twenty-four hours after IFN treatment, cells were infected with either VSV or mengovirus (multiplicity of infection, MOI=0.1). Cell death was quantified 24 h post-infection by determining visually the cytopathic effect (CPE) under an inverted phase-contrast microscope. CPE <30% was designated '-', ≥30% and ≤70% was designated '±' and >70% was designated '+'.
Results
Cell-based assay for inhibitors of HCV replication
We have previously shown that the 293B4α cell line expressed high levels of luciferase in response to the production of the HCV replicative proteins (King et al., 2002b) . To establish if this cell line could be used to identify chemical compounds capable of inhibiting the function of these proteins, we first determined the growth conditions that would maximize this possibility. These parameters included concentration of FBS in the medium, cell density and time interval between plating the cells and exposure to compound.
To determine how the concentration of FBS would affect the production of luciferase in 293B4α cells, cells were passed for approximately 30 days in DMEM that contained either 1%, 3%, 5% and 10% FBS to acclimate them to the particular FBS concentrations. Cells then were plated in 96-well microtitre plates (1×10 4 cells/well) in DMEM that contained the appropriate amount of FBS. Forty-eight hours later the cells were counted, lysed and the levels of luciferase were quantified ( Figure 1a ). Both final cell number and luciferase production was roughly equivalent in the wells that contained cells grown for 48 h in 3%, 5% and 10% FBS; whereas the number of cells in the wells that contained cells grown in 1% FBS was approximately 75% less. Likewise, the level of luciferase in the cells grown in 1% FBS was approximately 25% of the levels found in cells grown in 3%, 5% and 10% FBS.
To determine the effect of cell density on luciferase production, 293B4α cells that had been grown in 5% FBS were plated in 96-well plates at 1×10 3 , 3×10 3 , 1×10 4 and 3×10 4 cells/well. Forty-eight hours later, cells were lysed and luciferase levels were quantified (Figure 1b ). Cells plated at 1×10 4 cells/well produced the most luciferase, whereas those plated at 1×10 3 and 3×10 3 cells/well produced approximately 10% and 33% of this level, respectively. Cells plated at 3×10 4 cells/well consistently produced less than those plated at 1×10 4 cells/well, which may be due to the fact that the monolayer was extremely overcrowded and was starting to detach from the plate.
To establish if the actual plating process affected luciferase production, we plated cells (1×10 4 cells/well) in DMEM+5% FBS. Cells were incubated for 1, 2, 3 and 4 days, lysed and the luciferase levels were quantified ( Figure  1c ). Cells that were harvested one day after plating had the highest level of luciferase; whereas cells harvested two days and three days after plating produced approximately 20% and 30% less luciferase, respectively. Four days after plating all cells had become overcrowded and had detached from the wells.
Inhibition of HCV replication by 3′-deoxynucleoside analogues
We formatted the 293B4α cell line into an assay in which 3×10 3 cells were plated per well in DMEM + 5% FBS. Twenty-four hours later, various concentrations of test compound were added to the cells and the cells were incubated for 36-48 h at 37°C. Cells were lysed and luciferase was quantified as described in Materials and methods. We also determined the cytotoxicity of the compounds by using the same protocol with 293SVLuc cells instead of 293B4α cells. Previously we validated this methodology for determining cytotoxicity by comparing the inhibition of luciferase production by known cytotoxic compounds and compared the TC 50 and TC 90 determined in this system with those established by thymidine uptake and XTT assays. We found that the TC 50 and TC 90 values determined in these three assays varied by less than twofold (data not shown).
293B4α and 293SVLuc cells were treated with several concentrations of 3′-deoxyadenosine, 3′-deoxycytidine, 3′deoxyguanosine, 3′-deoxyuridine and lamivudine (0.5-150 µM). Forty-eight hours post-treatment, the cells were lysed and luciferase was quantified (Figure 2a ). 3′-deoxycytidine inhibited luciferase in the 293B4α cell line (IC 50 =34 µM) but did not affect the level of luciferase in the 293SVLuc cells. 3′-deoxyadenosine inhibited luciferase in both cell lines (IC 50 and TC 50 approximately 100 µM); whereas 3′deoxyguanosine, 3′-deoxyuridine and lamivudine did not have any affect on luciferase levels in either cell line at the concentrations tested.
To ensure that the decrease in the luciferase level in the 3′-deoxycytosine-treated 293B4α cells was due to an inhibition of the replication of the HCV-like RNA template and not a specific inhibition of luciferase activity, we determined the amount of luciferase protein made in these cells by Western blot analysis (Figure 2c ). We found that the level of luciferase protein decreased in a dose-responsive fashion as the concentration of 3′-deoxycytosine was increased.
Inhibition of HCV replication by interferon and ribavirin
IFN and IFN+ribavirin are the two therapy regimens that are currently approved for the treatment of HCV infection (Lavachy et al., 1999; McHutchison et al., 1998) . To determine if IFN-α and -β, and ribavirin were able to inhibit HCV replication in the 293B4α cell line, cells were treated with various concentrations of IFN, ribavirin and a combination of IFN and ribavirin. Five days post-treatment, cells were lysed and luciferase levels were quantified (Figure 2b) .
IFN-α and -β had anti-HCV activity in the 293B4α cell line but did not inhibit luciferase in 293SVLuc cells (IFN-α: IC 50 =263 IU/ml, TC 50 >1000 IU/ml; IFN-β: IC 50 =79 IU/ml, TC 50 >1000 IU/ml); whereas ribavirin had little or no effect above cytotoxicity (IC 50 =3 µM, TC 50 =8 µM). In combination, ribavirin did not potentiate the ability of IFN to inhibit HCV replication in these cells (Table 1) . Furthermore, when IFN-α and -β were used in combination, they too acted additively to inhibit HCV replication.
IFN-induced antiviral state in 293 and HUH-7 cells
Interestingly, IFN-α is approximately 10-100-fold less potent in our system than what has been reported in the subgenomic HCV RNA systems (Blight et al., 2000; Chung et al., 2001; Gou et al, 2001; Lohmann et al., 1999) . There may be many explanations for this discrepancy; for example, differences in cell lines, levels of virus replication or the antiviral state induced by IFN may all account for this disconnect in the potency of IFN.
To determine if there was a difference in the IFNinduced antiviral states between 293 (parental line of the 293B4α cell line) and HUH-7 cells (parental cell line for the HCV subgenomic replicon cell lines), we pretreated both cell lines with various concentrations of IFN-α for 24 h and then infected them with VSV or mengovirus. Twenty-four hours post-infection, we determined CPE under an inverted phase-contrast microscope. We found that both IFN-α and -β induced a more robust antiviral state against both VSV and mengovirus in the HUH-7 cell line than in 293 cells (Tables 2 and 3 ).
Discussion
Infection by HCV is one of the major causes of liver disease. Acute infections can lead to chronic hepatic disease, cirrhosis, liver failure and liver cancer; whereas chronic infection often leads to liver failure and the need for liver transplant (Lavachy et al., 1999) . Currently, IFN-α monotherapy or combination therapy with ribavirin are the only approved treatments for patients with chronic HCV. However, treatment failure is quite high with only about 40% of treated individuals responding to therapy RW King et al. 368 ©2002 International Medical Press ( McHutchison et al., 1998) . This number can be increased to approximately 60% with the use of a pegylated form of IFN-α (Shiffman et al., 1999) . Because of the low response rate to the currently approved treatments, there is still a serious need for more efficacious anti-HCV therapies. Topping this list of potential therapies are low molecular weight, organic compounds that are orally bioavailable. These could be targeted against the virus' enzymatic proteins; for example, the NS5B RdRp (both nucleoside analogues and non-nucleoside analogues), the NS3 serine protease, the NS3 helicase and the NS2 protease. Much effort has been put into creating and running large chemical libraries of chemical compounds through high throughput screens for these potential virus targets; however, the development of the compounds identified in these screening efforts has been hindered by the lack of a good cell-based system that models the HCV replication cycle.
In attempts to overcome this, several labs have reported the use of the bovine viral diarrhoea virus as a surrogate system for HCV drug discovery (Zitzmann et al., 1999; Bukhtiyarova et al., 2002) . However, several cell-based systems have recently been described that model portions of the HCV replication cycle that allows for identifying potential inhibitors of HCV replication (Moradpour et al., 1998; Lohmann et al., 1999; Blight et al., 2000; King et al., 2002b) . In many of these systems, treatment of the cells with IFN-α inhibits the production of HCV RNA (Lohmann et al., 1999; Blight et al., 2000; Gou et al, 2001) . It has been reported that in these systems, IFN-α acts in an Mx-independent method that may involve an interaction of HCV NS5A and the PKR system (Gale et al., 1997 (Gale et al., , 1998 Murkami et al., 1999; Frese et al., 2001) , as well as other novel, yet unidentified IFN-induced antiviral pathways (Francois et al., 2000) . In our cell-based system, IFN inhibited HCV RNA synthesis in a dose-responsive manner; however it was 10-100-fold less potent than in the other HCV cell-based replication systems.
To try to elucidate the reason for this difference, we treated both HUH-7 and 293 cells with IFN-α and -β and infected them with VSV and mengovirus, viruses known to be sensitive to the antiviral effects of IFN. We found that both viruses were more resistant to the IFNinduced antiviral state established in 293 cells than the one established in HUH-7 cells. Therefore, we speculate that the reason the IFN-α was less potent in our system than the HCV replicon based systems was due, at least in part, to the less robust antiviral state induced by IFN in the 293 cells.
In our system, we could not separate the antiviral effects of ribavirin from its cytotoxicity. This would not be unexpected if the mechanism of action of ribavirin is as reported as a mutagen of RNA viruses (Crotty et al., 2000 (Crotty et al., , 2001 Maag et al., 2001) . Since, in our system, the 'negativestrand' is transcribed from the integrated reporter cassette by the host's DNA-dependent RNA polymerase, which has little or no affinity for ribavirin, ribavirin-induced mutagenesis should not occur at this step. The HCV RdRp catalyzed step of the production of 'positive-strand' RNA from the 'negative strand', which is susceptible to the mutagenic potential of ribavirin, may cause the incorporation of ribavirin for cytosine and uridine. If the mutation occurs at this step, depending on where the mutation occurs, it may have little or no effect on luciferase production since the mutations caused by ribavirin seems to negatively affect RNA synthesis, not protein translation (Crotty et al., 2000) . However, an alternative or additional mechanism for the inhibition of HCV replication by ribavirin has been proposed (Borowski et al., 2001) . In an HCV NS3 helicase assay, ribavirin acted to inhibit the unwinding of duplex RNA in a way that was independent of an inhibition of the associated NTPase activity. If ribavirin truly acts in this way, it was not detected in our system. 
